Angiotensin II receptor Inhibitors
3 drugsAbout Angiotensin II receptor
The Angiotensin II receptor is a key component of the renin-angiotensin-aldosterone system (RAAS), regulating blood pressure and fluid balance. As a receptor protein, it mediates vasoconstriction and aldosterone release, increasing blood pressure. Modulation of this receptor is a successful therapeutic strategy for cardiovascular conditions.
Blocking the Angiotensin II receptor lowers blood pressure and reduces cardiovascular event risk. Currently, there is no genetic evidence available linking the Angiotensin II receptor to specific diseases. The clinical success of existing drugs underscores its importance as a therapeutic target.
Three FDA-approved drugs target the Angiotensin II receptor, including EXFORGE, AZOR and EXFORGE HCT, all small molecules. These drugs, developed by Novartis and COSETTE, are used in cardiovascular therapeutic areas. EXFORGE was the first approved drug in 2007.
Top Angiotensin II receptor Drugs
Novartis and COSETTE are the only two companies with approved drugs targeting this receptor.
The concentrated market suggests high barriers to entry or limited innovation by other players.
Angiotensin II receptor Drug Modality Landscape
Modalities
Routes of Administration
Angiotensin II receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Angiotensin II receptor Clinical Trials 124 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Angiotensin II receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 34 | 31 | 1 | 2 | 97% |
| Phase 2 | 15 | 12 | 1 | 2 | 92% |
| Phase 3 | 29 | 22 | 5 | 2 | 81% |
| Phase 4 | 46 | 28 | 10 | 8 | 74% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Angiotensin II receptor Drug Approval Timeline (2007 - 2009)
The first drug was approved in 2007, and the most recent in 2009, spanning a 3-year period.
The lack of recent approvals suggests a saturated market or challenges in developing new drugs for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 74 (31 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Angiotensin II receptor. A trial counts if an approved drug acting on Angiotensin II receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.